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Occupational asthma 
in Australia
Highlights
About 9–15% of adult-onset asthma cases can be attributed to exposures at work. Precise 
data are not available, but based on research from Australia and overseas, there may be as 
many as 1,000–3,000 new cases of occupational asthma each year in Australia. People with 
occupational asthma often have to change jobs or careers to relieve their symptoms; hence, 
work disruption and economic hardship are common consequences of the disease.
Occupational asthma is a type of asthma where the cause is often acknowledged. 
Individuals at high risk of developing this disease include those with a family history of 
asthma, previous sensitisation to one or more allergens, exposure to tobacco smoke, and, 
most importantly, employment in a high-risk workplace. 
Numerous workplace agents (300–400 to date) can cause occupational asthma in 
susceptible individuals. Among the most common causes of occupational asthma in 
Australia are wood dust from trees such as the Western red cedar, isocyanates (the 
raw materials used in polyurethane products), paint fumes, solvents, latex, and ﬂour. 
Manufacturing and health/community services tend to be the industries with the 
workplaces of highest risk. 
Although not curable, occupational asthma is largely preventable through actions that 
avoid or reduce exposure to workplace sensitisers and irritants. The ability to predict which 
people are likely to develop occupational asthma is mixed and requires further investigation 
and review. There is also a need to gather more systematic data on the causes, prevalence, 
incidence and impact of occupational asthma in Australia.
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Introduction
Asthma is a chronic inﬂammatory disease of the airways that aﬀects more than 2 million 
Australians. A great deal has been learned about this complex disease in recent years, 
including the factors that provoke attacks or worsen symptoms. However, the exact causes 
are largely unknown and the relationships between the key characteristics of asthma (see 
Box 1) are not fully understood (O’Byrne & Inman 2003; Pearce et al. 1999; Prescott & 
Tang 2004). Asthma can develop at any time in life but it has been estimated that about 
50–60% of all cases develop in adulthood (Flattery et al. 2006). Among adult-onset cases, 
clear causal relationships can sometimes be established between the disease onset and 
exposure to agents in the workplace.
Asthma caused by exposure to agents in the workplace is commonly referred to as 
occupational asthma. Together with pre-existing asthma provoked or worsened by 
environmental conditions or substances at work (work-aggravated asthma), it is one of 
the most commonly reported occupational respiratory disease in Australia and other 
developed countries (ASCC 2006; Banks & Jalloul 2007; Elder et al. 2004; McDonald  
et al. 2000; Newman Taylor et al. 2004). 
Occupational exposure accounts for up to 15% of new asthma cases in adults. However, as 
a type of asthma with known causes, occupational asthma is largely preventable through 
the eﬀective control of exposure to causal agents. This bulletin addresses several key 
questions regarding this form of asthma:
1. What is occupational asthma? (How is it deﬁned, what are the diﬀerent types, and in 
what ways does is diﬀer from ‘normal’ and work-aggravated asthma?)
2. What causes it? (What are the factors that increase the risk of occupational asthma 
and which occupations present the greatest risks?)
3. How common is the disease? (What is the prevalence and incidence of occupational 
asthma in Australia?)
4. What are its consequences? (How does occupational asthma aﬀect the individual and 
the health-care system?).
Accurate measures of the prevalence and incidence of occupational asthma can be used 
to target where interventions are needed and to monitor and evaluate their eﬀects. 
This bulletin includes a discussion of the monitoring and surveillance of the disease and 
its risk factors.
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Box 1: Definition and characteristics of asthma
Asthma is defined by the expert panel of the National Asthma Education and Prevention Program, 
US National Heart, Lung, and Blood Institute, as:
‘… a chronic inflammatory disorder of the airways in which many cells and cellular elements play 
a role, in particular, mast cells, eosinophils, T lymphocytes, neutrophils, and epithelial cells. In 
susceptible individuals, this inflammation causes recurrent episodes of wheezing, breathlessness, 
chest tightness, and cough, particularly at night and in the early morning. These episodes are 
usually associated with widespread but variable airflow obstruction that is often reversible either 
spontaneously or with treatment. The inflammation also causes an associated increase in the 
existing bronchial hyperresponsiveness to a variety of stimuli’ (National Asthma Education and 
Prevention Program 1997:3).
About occupational asthma
Occupational asthma is new-onset asthma in which the underlying cause is exposure to 
an agent at work. It is distinguished from work-aggravated asthma in that the individual 
has not had asthma previously. That is, in occupational asthma, workplace exposures 
cause  new cases of asthma, while in work-aggravated asthma, workplace exposures 
provoke (or ‘trigger’) symptoms of existing asthma. Up to 15% of cases of asthma in 
working-age adults can be attributed to exposures in the workplace (Balmes et al. 2003; 
Blanc & Toren 1999). 
Occupational asthma can be either allergic or non-allergic (see Box 2). Allergic 
occupational asthma is often referred to as sensitiser-induced occupational asthma, while 
non-allergic occupational asthma is commonly referred to as irritant-induced occupational 
asthma. Sensitisers are agents that make the airways sensitive so that they react to 
subsequent exposure to the same agent and often to other sensitisers, irritants and triggers 
such as cold air. Therefore, people with sensitiser-induced occupational asthma are 
sensitised to at least one allergen in their workplace, which on subsequent exposure causes 
an allergic immune response in the airways. Irritants are agents, such as chemicals, that 
cause adverse reactions in the airways, particularly localised inﬂammation. 
Approximately 90% of occupational asthma is sensitiser-induced, with the remaining 10% 
being irritant-induced (Henneberger et al. 2003; Newman Taylor et al. 2004; Tarlo & 
Liss 2003). Some people with work-aggravated asthma may also be sensitised to agents in 
the workplace and develop occupational asthma (Banks & Jalloul 2007).
Whereas sensitiser-induced occupational asthma involves an allergic immune response, 
irritant-induced occupational asthma occurs shortly after a high level of exposure at work 
to a respiratory irritant such as a gas, smoke, fume or vapour (Alberts 1996; Chatkin 
et al. 1999). It may result from a single or multiple high-level irritant exposures. While 
the precise mechanism involved in irritant-induced occupational asthma is not known 
(Lombardo & Balmes 2000; Mapp et al. 2005), inﬂammation following injury to the 
bronchial epithelium is a likely initial stage.
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In sensitiser-induced occupational asthma, there is a time delay between ﬁrst exposure and 
the onset of symptoms (Youakim 2001). The time delay can vary depending on biological 
variability, the causal agent and the management of exposure. The delay can be many 
years; however, occupational asthma is most likely to develop in the ﬁrst years of exposure 
for workers exposed to agents such as isocyanates, laboratory animal allergens, platinum 
salts and enzymes (Newman Taylor et al. 2004). For irritant-induced occupational 
asthma, the sudden onset of asthma occurs within hours of exposure to very high 
concentrations of inhaled irritants in the workplace (Vandenplas & Malo 2003).
Box 2: Allergic and non-allergic asthma 
Approximately 65–80% of asthma cases are the result of an allergic immune response occurring in 
the airways (Court et al. 2002; Faniran et al. 1999; Miraglia Del Giudice et al. 2002; Plaschke et al. 
1999). People with this form of asthma are sensitised to at least one allergen in their environment 
and are therefore said to have allergic (or immunologic) asthma. Their allergic immune response is 
mediated by certain antibodies, especially immunoglobulin E (IgE), and is often referred to as IgE-
mediated hypersensitivity (or Type 1 hypersensitivity). Pre-existing allergic sensitisation, or atopy, 
is an important risk factor for the development of allergic asthma (Faniran et al. 1999; Illi et al. 
2001; Lombardo & Balmes 2000). Other risk factors include a family history, tobacco smoking and 
exposure to allergens (e.g. house dust mites, cats, cockroaches, pollen and moulds).
In contrast with allergic asthma, non-allergic (or non-immunologic) asthma does not involve 
sensitisation and may be caused by a chemical irritant or virus, among other yet-to-be-discovered 
causes (Novak & Bieber 2003). Risk factors for non-allergic asthma include tobacco smoking and 
exposure to irritants in the workplace. Non-allergic asthma is less frequently associated with a 
family history of asthma (Nieves et al. 2005).
Allergic and non-allergic asthma share more similarities than differences. For example, even 
though the risk factors for the two types are different, the inflammatory response in the airways 
is very similar and the symptoms are essentially the same (Novak & Bieber 2003). An important 
difference involves the specificity of airway hyperresponsiveness (AHR) that people with allergic 
or non-allergic asthma tend to have. People with allergic asthma typically have specific airway 
AHR, which means their airways respond and narrow when re-exposed to small amounts of the 
original sensitising agent. They usually also have non-specific AHR, in which their airways narrow 
when exposed to non-specific triggers such as exercise, cold air, air pollutants, viruses, and some 
medications and food preservatives. Those with non-allergic asthma usually have non-specific 
AHR, but they tend not to have specific AHR (Youakim 2001).
Reactive airways dysfunction syndrome
Irritant-induced occupational asthma results from one or more exposures to a respiratory 
irritant. A subtype of irritant-induced occupational asthma is ‘reactive airways dysfunction 
syndrome’ (RADS), which results from a single exposure to high concentrations of an 
irritant (Brooks et al. 1985). RADS occurs within 24 hours of a single exposure large 
enough to cause injury to the airways. Unlike other types of occupational asthma, 
RADS is typically not preceded by sensitisation. 
bulletin 59 • april 2008
5
People with RADS have respiratory symptoms that persist for at least 3 months. The 
acute symptoms are probably associated with airway inﬂammation following epithelial 
injury—but the reasons for the persistence of symptoms are unclear (Alberts 1996). 
Whereas allergic occupational asthma is induced only by sensitisers, RADS can be caused 
by substances that are purely irritants as well as those that may act as sensitisers for other 
people, provided the exposure is at irritant level (Banks 2001). A substance such as toluene 
diisocyanate may be a sensitiser for some people and, at higher concentrations, an irritant 
for others (Banks 2001; Chatkin et al. 1999).
RADS is characterised by reversible bronchial constriction as well as airway inﬂammation 
and hyperresponsiveness (as with sensitiser-induced occupational asthma). However, 
RADS is not associated with a latency period between exposure and onset of symptoms 
(unlike sensitiser-induced occupational asthma), and people with RADS do not have 
subsequent attacks when exposed to small amounts of the causal irritant (Alberts 1996). 
To distinguish it from irritant-induced occupational asthma of a delayed or progressive 
nature, RADS may be best considered as ‘acute irritant-induced asthma’ or as ‘sudden-
onset irritant-induced asthma’ (Francis et al. 2007; Mapp et al. 2005; Vandenplas & 
Malo 1997).
In terms of persistence of symptoms, use of health-care services, days oﬀ work, and 
applications for workers’ compensation, the impact of RADS is at least as great as that 
of other occupational and work-aggravated asthma (Henneberger et al. 2003). However, 
accounting for probably less than 1% of adult asthma, RADS is relatively rare in Australia 
(Johnson et al. 2006b).
Occupational risk factors
Risk factors for asthma are anything that increases the chance of developing the disease. 
These include factors that predispose an individual to developing asthma, agents that 
cause the onset of asthma, and factors that trigger or worsen symptoms in those with 
existing disease. Asthma may actually be a cluster of related diseases rather than a single 
disease (Burke 2003; van Woerden 2004; Wardlaw et al. 2005). Consequently, the causes 
and risk factors for asthma are varied. 
In occupational asthma, exposure to certain agents at work causes new cases of the 
disease; whereas in work-aggravated asthma, symptoms are made worse or more frequent 
by exposure to triggers at work. This section describes some of the known risk factors 
for occupational asthma. These include tobacco smoking, previous allergic sensitisation 
and genetic predisposition (Newman Taylor et al. 2004; Venables & Chan-Yeung 
1997). However, ﬁndings from several studies, including cohort studies, show that the 
level of exposure to workplace sensitisers and irritants is most important for developing 
occupational asthma (Gautrin et al. 2003; Newman Taylor 2002; Sastre et al. 2003; 
Tarlo et al. 1997). In other words, if exposure does not occur, the disease will not occur 
(Curran & Fishwick 2003).
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Causal agents (sensitisers and irritants)
There are numerous agents (at least 300–400 to date) that have been cited as causing 
occupational asthma. In Finland, an estimated 30% of the total workforce is exposed to 
respiratory pollutants in the workplace, and about 13.5% are exposed to occupational 
sensitisers (Rantanen & Lehtinen 1992, cited in Reijula et al. 1996). Data from the 
Finnish Registry of Occupational Diseases show that about 69% of occupational asthma 
cases are caused by ﬂours, grain dusts, fodders and the skin, hairs and secretions of 
animals (Karjalainen et al. 2000).
Occupational asthma is caused by workplace agents that have either a high or low 
molecular weight (Table 1). Common high molecular weight substances include latex, 
ﬂour, grains, enzymes and laboratory animal antigens; common low molecular weight 
causal agents include isocyanates and Western red cedar dust.
Table 1: Selection of high and low molecular weight agents causing occupational asthma 
High molecular weight agents Low molecular weight agents
Animal Chemicals
Animal allergens (e.g. dander, urine) Isocyanates (e.g. toluene diisocyanate)
Crustaceans (prawns, crabs) Acid anhydrides
Egg protein Complex amines
Bird products Reactive dyes
Arthropods Methyl methacrylate
Plants Glutaraldehyde
Grain dust Formaldehyde
Coffee bean dust Metal salts, dusts or fumes
Wheat flour Platinum
Rye flour Cobalt
Soy flour Chromium
Latex Nickel
Plant allergens (e.g. pollens) Wood dusts
Fungi Western red cedar
Moulds Redwood
Yeasts Oak
Enzymes Pharmaceuticals
Pancreatin Penicillins
Pepsin Tetracycline
Trypsin Other
Fungal amylase Colophony in solder flux
Alcalase Aluminium potroom emissions
Sources: Chan-Yeung & Malo (1994); Lombardo & Balmes (2000); Mapp et al. (2005); Venables & Chan-Yeung (1997).
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The distinction between high molecular weight (HMW) and low molecular weight 
(LMW) agents is important as it appears that the size of the causal agent aﬀects the 
disease mechanism—the mechanism for HMW agents being better understood 
(Youakim 2001). High molecular weight agents, such as animal and vegetable proteins, 
seem to act through immunoglobulin E (IgE)-mediated hypersensitivity. That is, they 
cause sensitiser-induced occupational asthma by stimulating the production of IgE 
antibodies in an early-phase allergic immune response (Mapp et al. 2005).
On the other hand, LMW agents, which include organic and inorganic compounds, 
cause a less well-deﬁned immune response that generally does not involve an IgE-
mediated allergic immune response (Mapp et al. 2005). This includes the majority of 
LMW chemicals, such as isocyanates, Western red cedar and acrylates. However, some 
LMW agents usually do act through IgE-mediated hypersensitivity; these include acid 
anhydrides, platinum salts and reactive dyes (Sastre et al. 2003; Vandenplas et al. 2003; 
Venables & Chan-Yeung 1997).
Most of the studies demonstrating a direct relationship between allergen exposure at 
work and occupational asthma also showed a positive exposure–response relationship 
for sensitisation. This means that higher exposure to many of the causal workplace 
agents increases the risk of sensitisation and occupational asthma, particularly for agents 
acting through IgE-mediated hypersensitivity, such as ﬂour allergens, laboratory animal 
allergens, acid anhydrides, platinum salts and enzymes (Sastre et al. 2003). 
At-risk occupations
At-risk occupations are those in which workers may be exposed to suﬃcient levels of 
causal agents to develop occupational asthma. Surveillance systems and population-based 
studies have found the occupations with the greatest risk for occupational asthma to be 
farming, painting, cleaning, baking, animal handling (e.g. veterinary care and laboratory 
technicians) and chemical work (Karjalainen et al. 2000; Kogevinas et al. 1999; Newman 
Taylor et al. 2004; Reijula et al. 1996). Other at-risk occupations include nursing, welding, 
food processing, dentistry, laboratory work, storage work, and work in the timber, forestry, 
electrical, electronic production, metal, plastics, rubber, and textile industries (Newman 
Taylor et al. 2004).
When causal agents are examined individually, the incidence of asthma can vary greatly 
and covers a wide variety of occupations (Table 2).
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Table 2: Selected causal agents, incidence and occupations in which exposure may occur 
Agent Incidence in exposed subjects Associated occupations
Isocyanates Approximately 5% Adhesive industry, automotive industry, carpenter, chemical industry, 
coachworks, foundry worker, joiner, mechanic, metallurgist, painter, 
plastics industry, tinsmith
Wood dust 3.4–13.5% Builder, carpenter, joiner, model builder, paper industry, polisher, 
sander, saw mill employee, woodcutter
Flour and grain dust Proportional to the frequency and 
duration of the exposure to the risk 
and directly related to the workplace 
conditions for some agents
5–24% for others
Animal breeder, animal foodstuffs industry, baker, butcher, 
cannery factory employee, coffee packer, combine harvester driver, 
confectioner, cook, delicatessen employee, docker, food industry, 
grocer, miller, pastry cook, pizza maker, seed packer
Animals 10–32% Animal breeder, biologist, food processing industry, pet shop 
employee, pharmaceutical industry, veterinary surgeon
Latex 2.9–5.5% and attains 8% in subjects 
who are regularly exposed to this 
product
Toy manufacture, hospital staff, surgical glove manufacture, medical 
personnel, nurse, surgeon, textile industry
Formaldehyde 30% Carpenter, chemical industry, cosmetics industry, embalmer, foundry 
worker, hairdresser, laboratory staff, medical personnel, nurse, paper 
industry, plastics industry, rubber industry, tanner
Platinum salts 10% with precautions in place  
(>50% initially)
Chemist, dentist, electronic components industry, electronics industry, 
jeweller, metallurgist, nurse, photographer, refinery worker
Source: Asmapro (2006).
In Australia
An occupational respiratory surveillance scheme in Victoria and Tasmania (Surveillance 
of Australian Workplace Based Respiratory Events—SABRE) reports on the causal 
agents of occupational asthma cases in these states. Wood dust from trees such as the 
Western red cedar (accounting for 13.5% of reported diagnoses) and isocyanates (5.8%) 
were the most common causal agents reported in the ﬁrst 3.5 years of the scheme (Elder 
et al. 2004). Other causal agents commonly reported in Victoria and Tasmania were 
paint fumes, aluminium potroom gas/fumes, solvents, latex, ﬂour and products of thermal 
combustion such as tobacco smoke. It should be noted, however, that the distribution 
of high-risk industry sectors, such as underground mining, diﬀers in these two states 
compared to the rest of Australia (Elder et al. 2004). Findings from SABRE, therefore, 
may not be representative of Australia as a whole.
Tobacco smoking
There is evidence that tobacco smoking worsens work-aggravated asthma (Mapp et 
al. 2005). There is also some evidence that tobacco smoking contributes to the risk of 
occupational asthma by increasing the likelihood of sensitisation by some causal agents 
(Lombardo & Balmes 2000; Youakim 2001). However, for some agents, studies provide 
conﬂicting evidence and the role of tobacco smoking is less clear. For example, when 
combined with smoking, exposure to isocyanates, platinum salts, salmon and snow crab 
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increases the risk of occupational asthma compared to exposure alone (Newman Taylor  
et al. 2004), but the relationship between smoking and the risk of developing occupational 
asthma is unclear when the causal agent is laboratory animals, enzymes or acid anhydrides 
(Newman Taylor et al. 2004).
Previous allergic sensitisation
Atopy is the tendency to produce IgE antibodies in response to exposure to low, usually 
harmless doses of common allergens (Johansson et al. 2001). The result of such exposure 
is an IgE-mediated allergic immune response, as seen in most cases of occupational 
asthma. Many studies have found that people with previous allergic sensitisation, 
particularly those with other IgE-mediated allergies, are more likely to be sensitised to 
agents encountered in the workplace, especially HMW substances (Huovinen et al. 1999; 
Jaakkola et al. 2006; Lombardo & Balmes 2000; Plaschke et al. 2000; Porsbjerg et al. 
2006; Wolfe et al. 2000; Xuan et al. 2002). 
In particular, it has been shown that in workers exposed to isocyanates, detergent 
enzymes, laboratory animals, other animals, some reactive dyes, or ﬂour, atopy increases 
the risk of occupational asthma (Newman Taylor et al. 2004). However, the evidence for 
an association between atopy and occupational asthma is conﬂicting for some agents. For 
example, some studies have failed to demonstrate an association involving isocyanates or 
detergent enzymes, as well as associations for agents such as cork, crab, salmon, platinum 
salts, and glutaraldehyde (Newman Taylor et al. 2004).
Occupational rhinitis (hay fever) is an IgE-mediated condition that frequently co-exists 
in people with sensitiser-induced occupational asthma (Huovinen et al. 1999; Malo 
et al. 2004; Nicholson et al. 2005). There is some evidence that the risk of developing 
occupational asthma is highest within a year of the onset of occupational rhinitis 
(Karjalainen et al. 2003; Nicholson et al. 2005). It has also been reported that people 
develop rhinoconjunctivitis—a combination of rhinitis and conjunctivitis (infection 
or inﬂammation of the membrane lining the eyelids)—before the onset of sensitiser-
induced occupational asthma (Grammer et al. 2002; Malo et al. 1997; Mapp et al. 2005; 
Nicholson et al. 2005). 
Genetic predisposition
Asthma most likely occurs when environmental factors aﬀect genetically susceptible 
individuals (Yang et al. 2007). The role of genetic susceptibility, or predisposition, 
in asthma has been demonstrated in studies of families, which have shown that 
approximately 50% of asthma risk is genetically determined (Cookson 2002; Host & 
Halken 2000). In particular, studies of twins demonstrate that genetically identical 
individuals (identical twins) have a higher probability of both individuals developing 
asthma than genetically similar but not identical individuals (fraternal twins) (Duﬀy et al. 
1990). Also, gene variants have been found that are more common in people with asthma 
than in those without asthma.
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Genetics may partly explain why an individual is allergic to a speciﬁc allergen (such as 
house dust mite or cat dander) but not another. Similarly, genetic predisposition may 
explain why not all individuals exposed to the same agent develop occupational asthma. 
For example, although diisocyanates are the LMW agents responsible for most cases 
of occupational asthma, only 5–10% of exposed workers develop the disease (Piirila  
et al. 2001).
The inheritance of asthma appears to be caused by multiple genes rather than a variation 
in a single gene, which means that the overall contribution of an individual gene or an 
individual gene variant may be quite low. Current knowledge suggests that asthma, 
and occupational asthma in particular, is a disease in which a large number of genetic 
variants are linked to subtle but harmful responses of the immune system and airways to 
environmental stimuli (Clarke et al. 2000; Patino & Martinez 2001).
Studies have shown that variants of certain genes may predispose a person to occupational 
asthma caused by a number of agents. For example, during the inﬂammation process, 
reactive oxygen damages tissues and causes some of the symptoms seen in asthma. 
Glutathione S-transferase (GST) is a family of enzymes that protects cells from reactive 
oxygen (oxidative stress) by acting as an antioxidant (McCunney 2005; Romieu et al. 
2004). Variants of the GST gene may be particularly important in protecting against 
immune responses to diisocyanate exposure (Piirila et al. 2001). The gene for another 
enzyme, N-acetyltransferase, may also be involved in diisocyanate-induced occupational 
asthma, especially when toluene diisocyanate is involved (Wikman et al. 2002).
Class II human leucocyte antigens (HLAs) have been shown to be important in 
occupational asthma caused by exposure to LMW chemicals, including acid anhydrides, 
isocyanates and platinum salts. In a study of Canadian workers that developed 
occupational asthma due to plicatic acid from the Western red cedar tree, 43% had one 
of two variants of the HLA DQB1 gene, while only 13% of the reference population had 
either of the gene variants (Horne et al. 2000). The HLA class II proteins are associated 
with the immune system’s recognition of foreign substances, such as viruses, bacteria and 
allergens. They have a crucial role in the immune response as they bind to parts of the 
proteins from these foreign entities and present them to white blood cells (T cells). The 
T cells then mount an immune response against those foreign (non-self) entities. Certain 
variants of the HLA genes have also been associated with IgE production following 
exposure to house dust mites and soybeans (Hizawa et al. 1998; Soriano et al. 1997). 
Other variants have been associated with sensitivity to apple, pollen, cockroach allergens, 
platinum salts and isocyanates (Balboni et al. 1996; Bignon et al. 1994; Donfack et al. 
2000; Kim et al. 2001; Mapp et al. 1997; Senechal et al. 1999; Stephan et al. 1999). 
As yet, there are no strong candidates for a genetic role in irritant-induced occupational 
asthma (Mapp 2003). However, among cases of irritant-induced occupational asthma 
that does not occur within 24 hours of exposure—that is, those that do not qualify as 
RADS—there may be an irritant–susceptibility interaction (Brooks et al. 1998).
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While several associations between occupational asthma and gene variants have been 
made, the evidence is often conﬂicting and the relative contribution of the genes in 
determining susceptibility is not known. In any event, the dose of the causal agent 
absorbed by an individual is the main factor inﬂuencing who develops occupational 
asthma (Gautrin et al. 2003; Newman Taylor 2002).
Prevalence and incidence
As with asthma in general, obtaining accurate estimates of the number of existing and new 
cases of occupational and work-aggravated asthma is challenging. Occupational asthma is 
a diﬃcult disease to diagnose as there is no single validated clinical questionnaire. Nor is 
there a single criterion for interpreting changes in lung function, such as peak expiratory 
ﬂow rates or bronchial hyperresponsiveness to speciﬁc agents (Moscato et al. 2003). There 
are also varying deﬁnitions of the disease and exposure (Lombardo & Balmes 2000). 
Notwithstanding these diﬃculties, administrative and survey data sources provide some 
indication of the prevalence and incidence of occupational and work-aggravated asthma. 
Before these data are examined, it is important to consider the proportion of adult-onset 
asthma that can be attributed to occupational exposures.
Attributing asthma to occupational exposures
Systematic reviews of studies from various countries have concluded that 9–15% of 
asthma cases in working-age adults can be attributed to occupational exposures (Balmes 
et al. 2003; Blanc & Toren 1999; Newman Taylor et al. 2004). This includes occupational 
(new-onset) asthma and reactivated pre-existing asthma (asthma that has been 
asymptomatic for a long time). Put another way, up to 15% of adult-onset asthma could 
be prevented if exposure to known occupational agents were avoided. In Australia, from 
a survey of about 5,300 adults aged 18–49 years in New South Wales in 2000–01, an 
estimated 9.5% of adult-onset asthma cases were due to occupational exposures (Johnson 
et al. 2006b). This estimate falls within the now widely cited and accepted 9–15% range.
Prevalence
The prevalence of occupational and work-aggravated asthma is usually estimated by 
population-based cross-sectional studies that rely on self-reports or, less commonly, 
clinical diagnosis. Case-control and clinical cohort studies are less common but normally 
involve clinical diagnosis. 
Population-based surveys—which typically rely on self-reports and do not contain strict 
criteria for work-related onset—are usually best suited for estimating the prevalence of 
work-aggravated asthma rather than occupational asthma. Results from such surveys 
suggest that work-aggravated asthma may be quite common. Surveys in Australia, the 
United States of America and Finland have found that 20–25% of workers with asthma 
report worse symptoms at work (Abramson et al. 1995; Henneberger et al. 2002; 
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Saarinen et al. 2003). The Australian study by Abramson and colleagues (1995) included 
adults in Victoria with a history of asthma or with symptoms of asthma. In Finland, 
Saarinen and colleagues (2003) found work-aggravated asthma among 10% of workers 
with child-onset asthma. 
Overall, the prevalence of occupational and work-aggravated asthma in Australia is 
diﬃcult to determine from available data. Based on estimates from the National Health 
Survey, 2.2% of asthma among adults in 2004–05 was reportedly work-related. This 
estimate is not limited to adult-onset cases.
Incidence
The incidence (new cases during a given period) of occupational asthma is most often 
estimated from case-based surveillance systems and medico-legal statistics, usually 
relying on physician reports.
Surveillance systems
Occupational asthma is considered a sentinel health event in some industrialised 
countries. That is, the disease has such implications for workplace health and safety 
that each new case serves as a warning for greater exposure prevention or control. 
The Surveillance of Work-related and Occupational Respiratory Disease (SWORD) 
system was introduced in the United Kingdom in 1989. It is a sentinel network operating 
under the Health and Occupation Reporting Network whereby specialists in thoracic and 
occupational medicine voluntarily report new cases of work-related respiratory disease.
A small number of states in the United States of America have surveillance and 
intelligence programs for occupational asthma as part of the Sentinel Event Notiﬁcation 
Systems for Occupational Risks (SENSOR). SENSOR is a state-based program funded 
by cooperative agreements awarded by the National Institute for Occupational Safety 
and Health. Physician reporting of occupational diseases is mandatory under SENSOR, 
but the requirement for supplementary hospitalisation data varies between states. 
Other systems that have operated or are still in use include the Notiﬁable Occupational 
Disease System in New Zealand, the Physician-based Surveillance System of 
Occupational Respiratory Disease in Quebec, Canada, the Surveillance of Work-related 
and Occupational Respiratory Diseases in South Africa system, and the Swedish Register 
of Reported Occupational Disease.
It is generally accepted that the recognition and reporting of work-related cases is less 
than systematic and therefore schemes such as SENSOR and SWORD probably 
underestimate the incidence of occupational asthma (Draper et al. 2003; McDonald et al. 
2000; Romero Jajosky et al. 1999). SWORD is also limited by not including consultations 
with general practitioners (McDonald et al. 2000).
bulletin 59 • april 2008
13
Finland has one of the most comprehensive occupational asthma notiﬁcation systems. 
Physicians in Finland are required to report all known or suspected cases of occupational 
disease to provincial labour protection authorities, which pass the information on to the 
Finnish Registry of Occupational Diseases (FROD). Insurance companies also report 
every new case of occupational disease to FROD. Duplication of cases is removed from 
the system, which covers about 95% of the workforce (Karjalainen et al. 2000). Due to 
strict criteria for the diagnosis of occupational asthma, mild cases requiring occasional 
medication tend not to be included in the register (Reijula et al. 1996).
In Australia
Two surveillance systems in Australia generate data on the incidence of occupational 
asthma. One is based on notiﬁcation of diagnosed cases, the other on workers’ 
compensation claims.
Surveillance of Australian Workplace Based Respiratory Events
The Surveillance of Australian Workplace Based Respiratory Events (SABRE) is an 
occupational respiratory disease surveillance (notiﬁcation) system that has operated in 
Victoria and Tasmania since 1997 and in New South Wales since 2001. The system 
involves voluntary and anonymous reporting by respiratory and occupational physicians of 
occupational respiratory events encountered in their practices. The coverage is incomplete 
in that it does not include all physicians who see cases of occupational respiratory diseases. 
Data from Victoria and Tasmania show that asthma is the most commonly reported 
occupational respiratory disease in these states. From November 1997 to October 2004, 
there were about 820 reported diagnoses of occupational respiratory disease (Sim et al. 
2005). Of these diagnoses, about 265 (32.5%) were of occupational asthma and about 200 
(24.5%) were of non-malignant pleural plaques. 
In contrast, the SABRE system in New South Wales contains about 3,190 diagnoses of 
occupational respiratory disease reported between January 2001 and November 2007 
(SABRE 2008). Of these diagnoses, 930 (29%) were of non-malignant pleural plaques, but 
only 80 (3%) were of occupational asthma.
The diﬀerences between the states in the reporting of occupational asthma may be due to 
actual diﬀerences in disease incidence (and causal factor prevalence), but it might also be 
due to under-reporting or under-diagnosis (Johnson et al. 2006a). 
The lack of complete coverage across and within states means that SABRE data cannot 
be considered representative of Australia as a whole. A senate inquiry into workplace 
exposure to toxic dust held in May 2006 recommended that the SABRE scheme operate 
nationally and be compulsory (Senate Community Aﬀairs References Committee 2006).
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The National Data Set for Compensation-based Statistics
The National Data Set for Compensation-based Statistics (NDS) consists of accepted 
workers’ compensation claims. That is, it contains data from Commonwealth, state 
and territory workers’ compensation agencies on cases that result in death, permanent 
disability or temporary disability involving 5 or more days oﬀ work. NDS data are used 
for occupational health and safety indicators. The data are available online via the Oﬃce 
of the Australian Safety and Compensation Council interactive database of national 
workers’ compensation statistics (ASCC 2008).
In the 5-year period from 2000–01 to 2004–05, there were about 2,660 accepted claims 
for respiratory diseases, about 395 of which (about 15%) were for asthma. During this 
period there were also about 945 accepted claims for asbestosis (about 36% of all accepted 
claims for respiratory diseases). Whereas the number of accepted claims for asbestosis has 
increased  from about 155 in 2000–01 to about 245 in 2004–05  (from 32% to 40% of 
accepted respiratory disease claims), accepted claims for asthma have fallen from about 95 
to about 70 (20% to 11%). 
In 2004–05, about 51% of the accepted asthma claims were for female workers, and about 
33% were for workers aged 45–54 years. Manufacturing (25%) and health/community 
services (23%) were the industries with the highest proportion of accepted claims. About 
11% of those with an accepted claim for asthma in 2004–05 were absent from work for 6 
months or more. 
NDS data do not cover all occurrences of occupational asthma as they do not include 
military personnel, self-employed workers, cases not claimed and cases not compensated 
under general Commonwealth, state and territory workers’ compensation legislation. 
Furthermore, the percentages reported may not be exact as the data are adjusted for 
conﬁdentiality purposes (hence the rounding to the nearest ‘5’).
Another shortcoming of the NDS, and similar compensation-based systems, is that timely 
diagnosis and the establishment of work-relatedness cannot be guaranteed. Consequently, 
many cases of asthma are not recognised as work-related and therefore not included in the 
database. This is often the situation with diseases that follow a long period of exposure or 
if there is a long latency between exposure and symptoms.
Incidence rates
A recent international study by Kogevinas et al. (2007) estimated the incidence rate 
of occupational asthma to be 250–300 cases per million people per year. This study 
included data from 13 countries, including Australia. Malo and Gautrin (2007), however, 
suggest that the Kogevinas et al. (2007) incidence rate probably underestimates the 
incidence of all types of asthma in the workplace, but overestimates the incidence of 
occupational asthma. 
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In Australia
An incidence rate of 250–300 cases per million workers per year as found by Kogevinas et 
al. (2007) would equate to about 2,400–2,900 cases of occupational asthma in Australia 
in 2003, given a labour force of about 9.5 million in that year. 
Estimates from the Australian Burden of Disease and Injury Study suggest that there 
were 78,493 new (incident) cases of asthma in 2003 (AIHW: Begg et al. 2007). About 
20,570 of these were in working-age adults (i.e. 15–64 years). Applying a population-
attributable risk of 9–15% to this estimate, there may have been between 1,850 and 3,090 
new cases of asthma in 2003 due to workplace exposures, giving an annual incidence 
rate of 195–325 cases per million workers per year (Table 3). This incidence rate range is 
similar to that proposed by Kogevinas et al. (2007), and includes a lower estimate similar 
to the average rate of 174 per million workers per year found in Finland by Karjalainen et 
al. (2000) and an upper estimate similar to the peak rate of 386 per million working-aged 
adults per year found by Reijula et al. (1996).
Some studies have attributed around 20% of adult-onset asthma to workplace exposures. 
For example, Johnson et al. (2000) estimated that 18% of adult-onset asthma in high-
risk occupations and industries in Canada could be prevented by avoiding exposure to 
known occupational agents. However, a population-attributable risk of 15% appears to 
be a reasonable upper limit based on the ﬁndings of comprehensive reviews and meta-
analyses (such as Balmes et al. 2003; Blanc & Toren 1999). On the other hand, in view of 
Malo and Gautrin’s (2007) observation, an attributable risk of 5% as found by Reijula et 
al. (1996) in Finland may be a more conservative lower limit for estimating the incidence 
of occupational asthma in Australia than the 9% concluded by Blanc and Toren (1999), 
or the 9.5% found by Johnson et al. (2006b). When 5% is used as the lower boundary for 
the estimate, it gives a lower number of 1,030 new cases in 2003. Overall, this gives an 
estimated annual incidence rate of 110–325 cases per million workers per year (Table 3).
Allowing for a considerable degree of imprecision in these estimates (such as that which 
may be caused by the lag between exposure and disease onset in some cases, labour force 
participation patterns, and the ratio of males to females in new cases of asthma compared 
with new cases of occupational asthma), they point to a problem that is much larger than 
suggested by the available surveillance and compensation statistics.
Table 3: Incidence of occupational asthma in Australia
Population-attributable risk 
(per cent)
Estimated number of cases 
(2003)
Incidence rate 
(cases per million workers per year)
5 1,030 110
9 1,850 195
15 3,090 325
Note: Estimates based on estimated number of new asthma cases in 15–64 year olds in 2003 (20,570) and labour force as of June 2003 (9,507,500).
Source: AIHW: Begg et al. 2007.
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Consequences
Deaths from occupational asthma are rare and only a handful of hospital separations in 
Australia can be identiﬁed as work-related. However, international studies have shown 
that occupational asthma is associated with considerable morbidity and economic burden 
(Larbanois et al. 2002; Vandenplas et al. 2003). 
There is often loss of income and associated ﬁnancial hardship among people with 
occupational asthma. Some people with the disease may have to change jobs or job duties 
to avoid exposure to the agent that caused their disease, reduce their participation in the 
workforce or take strict precautions against exposure whilst at work. Blanc et al. (1999) 
have found that almost a quarter of those aged 20–44 years in Sweden with occupational 
asthma reported having to change or leave jobs due to the eﬀects on their breathing. 
Occupational asthma can cause reduced job performance and lost work days. It can also 
leave a person severely disabled and consequently lead to early retirement. 
Unemployment rates are high among workers with occupational asthma, with around 
one-third of workers unemployed up to 6 years after diagnosis (Newman Taylor et al. 
2004). Between 25% and 38% of people with sensitiser-induced occupational asthma have 
prolonged periods of work disruption and as many as 78% experience a substantial loss of 
income (Vandenplas et al. 2003). 
Symptoms of occupational asthma are more likely to improve or even cease with an 
early intervention, such as early diagnosis and removal from exposure to the causal agent 
(Banks & Jalloul 2007; Newman Taylor et al. 2004; Venables & Chan-Yeung 1997). 
Many patients, however, fail to recover completely. Several years after removal from 
the causal agent, about 70% of people with sensitiser-induced occupational asthma still 
experience symptoms and non-speciﬁc bronchial hyperresponsiveness (Vandenplas et al. 
2003). People with irritant-induced occupational asthma may recover within months of 
ceasing exposure, but in some cases the symptoms persist for years or may be permanent 
(Alberts 1996). Both the duration of symptoms before removal from the causal agent and 
the severity of asthma at diagnosis have been associated with persistence of asthma. 
While removal from exposure to the causal agent increases the chance of improvement in 
health, it may also increase the ﬁnancial impact, which may explain why almost one-third 
of workers with sensitiser-induced occupational asthma remain exposed to the causal 
agent (Vandenplas et al. 2003). There is evidence that a reduction in exposure is less 
eﬀective than avoidance in reducing the worsening or persistence of symptoms and non-
speciﬁc bronchial hyperresponsiveness (Vandenplas et al. 2003). However, those who do 
not at least reduce their exposure to the causal agent and remain in the same job generally 
experience worsening asthma symptoms (Venables & Chan-Yeung 1997). 
The few available studies into the socioeconomic impact of work-aggravated asthma show 
that it is also associated with a sizeable socioeconomic impact. In two studies, the rate 
of unemployment and the proportion of people reporting a reduction in income did not 
diﬀer signiﬁcantly in comparison to those with occupational asthma (Cannon et al. 1995; 
Larbanois et al. 2002). For example, a reduction in income has been found in up to  
60–65% of people with either occupational or work-aggravated (Cannon et al. 1995; 
Larbanois et al. 2002).
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In Australia
Focus groups have been conducted in Victoria to examine the experiences and health, 
social and economic burdens associated with occupational asthma (Sim et al. 2005). In 
agreement with international ﬁndings, people with occupational asthma experienced 
signiﬁcant economic impact in both the short and long term. Sim and colleagues also 
identiﬁed large social impacts among people with occupational asthma, including 
negatively aﬀected social status at and outside the workplace, loss of key friendships 
and support networks, negative impacts on personal sense of worth, and loss of faith in 
themselves and others. 
Data from the Oﬃce of the Australian Safety and Compensation Council online database 
of national workers’ compensation statistics show that a considerable proportion of 
accepted claims for asthma involve more than 12 weeks of time lost from work (Table 4), 
although the proportion has fallen in recent years.
Table 4: Time lost from work associated with accepted claims for asthma, 2000–01 to 2004–05  
(per cent of accepted claims)
Time lost 2000–01 2001–02 2002–03 2003–04 2004–05
1 week to less than 2 weeks 30.5 25.3 16.7 25.1 23.1
2 weeks to less than 12 weeks 30.0 30.1 34.7 35.6 45.6
12 weeks to less than 26 weeks n.a. 15.7 13.9 n.a. 10.0
26 weeks or more 24.6 21.0 27.8 27.3 11.4
Permanent incapacity 10.7 7.9 6.9 7.1 10.0
n.a. = data not available due to privacy restrictions.
Source: Online statistics interactive National Workers’ Compensation Statistics databases (see ASCC 2008).
Disease and exposure monitoring
Measuring the extent, impact and causes of occupational asthma has many practical 
implications. Eﬀective disease and exposure monitoring improves the capacity to make 
decisions for cost-eﬀective allocation of resources, target priority populations groups and 
monitor the impact of intervention strategies. 
As a type of asthma with known causal agents, occupational asthma is largely preventable 
and amenable to the surveillance and monitoring of its risk factors, prevalence and 
incidence. In recent decades, knowledge of the mechanisms involved in sensitiser-induced 
occupational asthma has improved considerably. However, large gaps remain in our 
understanding of the mechanisms involved in irritant-induced occupational asthma and 
those involved in sensitiser-induced occupational asthma caused by exposure to LMW 
substances (Lombardo & Balmes 2000). 
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Monitoring prevalence, incidence and impact
Population-based surveys, compensation statistics and surveillance systems give an 
indication of the extent and distribution of occupational asthma as well as the main 
causal agents and occupations involved (Curran & Fishwick 2003; Gautrin et al. 2003). 
Administrative databases (e.g. the AIHW’s National Hospital Morbidity Database) 
and population-based surveys (e.g. the Australian Bureau of Statistics’ National Health 
Survey) provide additional information on outcomes associated with occupational asthma. 
However, all of these sources have severe limitations; especially the lack of clear and 
reliable identiﬁers for occupational asthma. 
Findings from population-based surveys can provide an indication of the prevalence of an 
occupational disease or condition. However, if the survey is not actually population-based, 
it may be subject to biases reﬂecting the ‘healthy worker eﬀect ‘or ‘survivor eﬀect’. The 
healthy worker eﬀect is a bias associated with a general tendency for workers to be healthier 
than the wider population (Garcia & Checkoway 2003). The survivor eﬀect is a bias 
associated with the loss of susceptible or aﬀected individuals from the working population 
(Garcia & Checkoway 2003). Population-based surveys also tend to have high sensitivity 
(ability to identify probable cases) but low speciﬁcity (ability to distinguish between cases 
and non-cases); hence leading to overestimation of estimates (Gautrin et al. 2003). 
The National Workers’ Compensation Statistics Database contains data from 
Commonwealth, state and territory workers’ compensation agencies on cases of work-
related disease and injury. In theory, these data can be used to indicate the incidence 
of occupational asthma, however the derived incidence would almost always be an 
underestimate as not all cases can or do claim compensation. That is, occupational 
asthma is not a condition that is compensated routinely (Australian Centre for Asthma 
Monitoring 2004). In general, compensation statistics do not give an accurate indication 
of occupational asthma incidence.
At present, the major available data source for monitoring the incidence of occupational 
asthma is the Surveillance of Australian Workplace Based Respiratory Events (SABRE) 
scheme in Victoria, Tasmania and, more recently, New South Wales. The SABRE 
database is collected speciﬁcally for monitoring work-related respiratory diseases such 
as occupational asthma. A number of limitations of SABRE data have been identiﬁed, 
such as a low participation rate associated with the voluntary nature of the scheme and 
the accuracy of the physician’s identiﬁcation of the causal agents (Australian Centre for 
Asthma Monitoring 2004; Sim et al. 2005). Surveillance/notiﬁcation systems generally 
underestimate the incidence of occupational asthma. Besides a lack of universal coverage, 
this is because information from surveillance systems can be compromised by diﬀerences 
in deﬁning cases of occupational asthma, recognition of the disease, attribution to work 
exposures, and motivation of the physician to report cases, especially when the system is 
voluntary (Gautrin et al. 2003; Karjalainen et al. 2000). They may also lack data from 
primary care settings (Curran & Fishwick 2003).
Occupational asthma can place a heavy economic and social burden on the aﬀected 
individual. However, there is little information about the outcomes for individuals in 
Australia, such as changes in employment status, income, quality of life and functioning.
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Monitoring exposures
Although atopy and variants of the HLA class II genes are important risk factors 
for occupational asthma, the level of exposure is the most important determining 
factor (Gautrin et al. 2003; Newman Taylor 2002). This places a greater emphasis on 
monitoring and eliminating, or at least controlling, workplace exposures.
In general, the surveillance and monitoring of asthma risk factors, particularly 
environmental factors, is complicated by the conﬂicting evidence for causal roles of some 
of these factors and for the eﬀectiveness of exposure-avoidance strategies, especially with 
respect to the onset of asthma (Australian Centre for Asthma Monitoring 2005).
Public (i.e. government) surveillance and monitoring of occupational asthma typically 
concerns the prevalence and incidence of cases (e.g. case notiﬁcation, compensation claims, 
self-reports on population-based surveys). Exposure monitoring is usually conducted 
at the industry or workplace level in compliance with state and territory occupational 
health and safety legislation. For example, Victoria’s Occupational Health and Safety 
Regulations 2007 outline the employer’s duty to identify and record any hazardous 
substances in the workplace and to control the associated risk. The employer is also 
required under the regulations to undertake atmospheric monitoring, provided exposure 
standards are applicable and there is no requirement for health surveillance involving 
biological monitoring. 
National exposure standards and codes of practice for airborne substances in 
the workplace, including those recognised as sensitisers, exist under the National 
Occupational Health and Safety Commission Act 1985. However, these standards and 
codes of practices are not enforceable unless adopted by relevant Commonwealth, state 
or territory legislation.
Monitoring genetic predisposition
Genetic predisposition, or susceptibility, plays a signiﬁcant role in the development of 
asthma. Researchers are currently examining how underlying genetic predisposition 
aﬀects the response to an environmental exposure that may lead to the development of 
asthma. However, in most cases, the cause of asthma remains unknown and it is not 
currently possible to identify individuals that are likely to develop the disease. 
Atopy and atopic diseases such as allergic rhinitis are strong risk factors for asthma; 
but not all atopic people develop asthma. So, although testing for atopy may be feasible 
for some speciﬁc sensitisers—a positive skin-prick test for acid anhydrides or platinum 
salts, for example, is a good predictor of occupational asthma (Cullinan et al. 2003)—in 
general, the presence of atopy is not a good predictor of occupational asthma development 
(Mapp et al. 2005; Youakim 2001). As yet, the interactions between personal 
susceptibility factors and environmental factors are not well enough understood to justify 
preemployment screening (Lombardo & Balmes 2000; Youakim 2001).
At present, information about the genetics of occupational asthma has greater 
implications for the development of prevention or treatment strategies through the 
understanding of the cause and nature of the disease. 
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Glossary
Allergen: an antigen that causes IgE-mediated hypersensitivity (allergy).
Allergic (or immunologic) asthma: asthma that involves an allergic immune response in 
the airways. People with this form of asthma are sensitised to at least one allergen in their 
environment.
Antibody: an immune cell produced in response to a speciﬁc antigen.
Antigen: a substance that when recognised by the immune system as non-self causes the 
production of antibodies and an immune response.
Atopy: a tendency (usually inherited) to produce IgE antibodies in response to low doses 
of common allergens, leading to symptoms seen in asthma, allergic rhinitis and eczema. 
Causal agents: factors that cause individuals to develop asthma. They include sensitisers 
and irritants.
Gene: the basic unit of heredity, comprised of deoxyribonucleic acid (DNA) and 
occupying a speciﬁc location on a chromosome.
Gene variant: a naturally occurring variation in the DNA of a gene. Gene variations are 
usually harmless and are part of the genetic diversity in humans. They are also called 
‘polymorphisms’.
Genetic predisposition: an inherited increased risk of developing a disease. It is also 
called genetic susceptibility.
IgE (immunoglobulin E): an antibody that binds to mast cells and, when in contact with 
an antigen, causes the mast cell to release inﬂammatory mediators such as histamine.
IgE-mediated hypersensitivity: also called ‘Type 1 hypersensitivity’, the immediate 
allergic immune response stimulated by re-exposure to speciﬁc antigens. As seen in atopic 
diseases such as allergic asthma and hay fever. 
Immune response: the body’s defensive reaction to foreign antigens.
Incidence: number of new cases during a given period.
Inﬂammation: local immune response to injury, infection or allergy. It involves increased 
blood ﬂow, immigration of white blood cells and release of toxins resulting in redness, 
heat, swelling and pain.
Irritant-induced occupational asthma: non-allergic occupational asthma.
Isocyanates: highly reactive low molecular weight chemicals used in the production of 
polyurethane foams, coatings, adhesives and insulation materials.
Mast cell: an immune cell that releases histamine and other inﬂammatory mediators in 
an IgE-mediated immune response. Mast cells are found in connective tissue and do not 
circulate in the blood.
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Non-allergic (non-immunologic) asthma: asthma that does not involve an allergic 
immune response. Instead of sensitisation, the asthma may be caused by a chemical 
irritant or virus.
Occupational asthma: new-onset asthma where the cause of the asthma is exposure to 
an agent at work.
Prevalence: the number or proportion of cases among a population at a given time.
Risk factors: any environmental, chemical, physiological, psychological or genetic factors 
that increase the risk of developing a health disorder or other unwanted condition or 
event. In asthma, risk factors include those that predispose people to develop the disease, 
cause the disease, or trigger symptoms.
Sensitisation: the process of becoming hypersensitive to an allergen.
Sensitiser-induced occupational asthma: allergic occupational asthma.
T cell: a white blood cell that activates or regulates an immune response (includes helper 
T cells, suppressor T cells and killer T cells).
Triggers: factors that evoke or worsen symptoms in people who already have asthma. 
Some may also be causal factors.
Work-aggravated asthma: pre-existing or coincident asthma made worse by 
workplace exposures.
References
Abramson MJ, Kutin JJ, Rosier MJ & Bowes G 1995. Morbidity, medication and trigger factors in 
a community sample of adults with asthma. Medical Journal of Australia 162:78–81.
AIHW (Australian Institute of Health and Welfare): Begg S, Vos T, Barker B, Stevenson C, 
Stanley L & Lopez A 2007. The burden of disease and injury in Australia 2003. Cat. no. PHE 
82. Canberra: AIHW.
Alberts WM 1996. Reactive airways dysfunction syndrome—review article. Chest 109(6):1618–
26.
ASCC (Australian Safety and Compensation Council) 2006. Report on indicators for 
occupational disease. Canberra: ASCC.
ASCC 2008. Australian Safety and Compensation Council (follow link to workers’ 
compensation). Canberra: ASCC. Viewed 13 March 2008, <www.ascc.gov.au>.
Asmapro 2006. Table of agents and substances which can cause asthma. Montpellier, France: 
Asmapro. Viewed 15 December 2006, <http://www.asmanet.com/asmapro/agents.htm>.
Australian Centre for Asthma Monitoring 2004. Review of proposed National Health Priority 
Area asthma indicators and data sources. Cat. no. ACM 2. Canberra: AIHW.
Australian Centre for Asthma Monitoring 2005. Asthma in Australia 2005. Cat. no. ACM 6. 
Canberra: AIHW.
Balboni A, Baricordi OR, Fabbri LM, Gandini E, Ciaccia A & Mapp CE 1996. Association 
between toluene diisocyanate-induced asthma and DQB1 markers: a possible role for aspartic 
acid at position 57. European Respiratory Journal 9:207–10.
22
Occupational 
asthma in Aust
ralia
Balmes J, Becklake M, Blanc P, Henneberger P, Kreis K, Mapp CE et al. 2003. American 
Thoracic Society Statement: Occupational contribution to the burden of airway disease. 
American Journal of Respiratory and Critical Care Medicine 167:787–97.
Banks DE 2001. Workplace irritant exposures: do they produce true occupational asthma? 
Current Opinion in Allergy and Clinical Immunology 1:163–8.
Banks DE & Jalloul A 2007. Occupational asthma, work-related asthma and reactive airways 
dysfunction syndrome. Current Opinion in Pulmonary Medicine 13:131–6.
Bignon JS, Aron Y, Ju LY, Kopferschmitt MC, Garnier R, Mapp C et al. 1994. HLA class II 
alleles in isocyanate-induced asthma. American Journal of Respiratory and Critical Care 
Medicine 149:71–5.
Blanc PD, Ellbjär S, Janson C, Norbäck D, Norrman E, Plaschke P et al. 1999. Asthma-related 
work disability in Sweden. American Journal of Respiratory and Critical Care Medicine 
160:2028–33.
Blanc PD & Toren K 1999. How much adult asthma can be attributed to occupational factors? 
American Journal of Medicine 107:580–7.
Brooks S, Hammad Y, Richards I, Giovinco-Barbas J & Jenkins K 1998. The spectrum of irritant-
induced asthma: sudden and not-so-sudden onset and the role of allergy. Chest 113: 42–9.
Brooks S, Weiss MA & Bernstein IL 1985. Reactive airways dysfunction syndrome: persistent 
asthma syndrome after high level irritant exposure. Chest 88:376–84.
Burke W 2003. Genomics as a probe for disease biology. The New England Journal of Medicine 
349:969–74.
Cannon J, Cullinan P & Newman Taylor A 1995. Consequences of occupational asthma. British 
Medical Journal 311:602–3.
Chan-Yeung M & Malo J-L 1994. Aetiological agents in occupational asthma. European 
Respiratory Journal 7:346–71.
Chatkin JM, Tarlo SM, Liss G, Banks D & Broder I 1999. The outcome of asthma related to 
workplace irritant exposures: a comparison of irritant-induced asthma and irritant aggravation 
of asthma. Chest 116(6): 1780–5.
Clarke JR, Jenkins MA, Hopper JL, Carlin JB, Mayne C, Clayton DG et al. 2000. Evidence for 
genetic associations between asthma, atopy, and bronchial hyperresponsiveness. American 
Journal of Respiratory and Critical Care Medicine 162:2188–93.
Cookson W 2002. Genetics and genomics of asthma and allergic diseases. Immunological 
Reviews 190:195–206.
Court CS, Cook DG & Strachan DP 2002. Comparative epidemiology of atopic and non-atopic 
wheeze and diagnosed asthma in a national sample of English adults. Thorax 57:951–7.
Cullinan P, Tarlo S, & Nemery B 2003. The prevention of occupational asthma. European 
Respiratory Journal 22:853–60.
Curran AD & Fishwick D 2003. Occupational asthma: research, change and the 30% target. 
Annals of Occupational Hygiene 47(6):433–6.
Donfack J, Tsalenko A, Hoki DM, Parry R, Solway J, Lester LA et al. 2000. HLA-DRB1*01 
alleles are associated with sensitization to cockroach allergens. Journal of Allergy and Clinical 
Immunology 105: 960–6.
Draper A, Newman Taylor A & Cullinan P 2003. Estimating the incidence of occupational 
asthma and rhinitis from laboratory animal allergens in the UK, 1999–2000. Occupational 
and Environmental Medicine 60:604–5.
Duﬀy DL, Martin NG, Battistutta D, Hopper JL & Mathews JD 1990. Genetics of asthma and 
hay fever in Australian twins. American Review of Respiratory Disease 142:1351–8.
bulletin 59 • april 2008
23
Elder D, Abramson M, Fish D, Johnson A, McKenzie D & Sim M 2004. Surveillance of 
Australian workplace Based Respiratory Events (SABRE): notiﬁcations for the ﬁrst 3.5 years 
and validation of occupational asthma cases. Occupational Medicine (London) 54:395–9.
Faniran AO, Peat JK & Woolcock AJ 1999. Prevalence of atopy, asthma symptoms and diagnosis, 
and the management of asthma: comparison of an aﬄuent and a non-aﬄuent country. Thorax 
54:606–10.
Flattery J, Davis L, Rosenman KD, Harrison R, Lyon-Callo S & Filios M 2006. The proportion 
of self-reported asthma associated with work in three states: California, Massachusetts, and 
Michigan, 2001. Journal of Asthma 43:213–8.
Francis HC, Prys-Picard CO, Fishwick D, Stenton C, Burge PS, Bradshaw LM et al. 2007. 
Deﬁning and investigating occupational asthma: a consensus approach. Occupational and 
Environmental Medicine 64:361–5.
Garcia AM & Checkoway H 2003. A glossary for research in occupational health. Journal of 
Epidemiology and Community Health 57:7–10.
Gautrin D, Newman-Taylor AJ, Nordman H & Malo J-L 2003. Controversies in epidemiology of 
occupational asthma. European Respiratory Journal 22:551–9.
Grammer LC, Ditto AM, Tripathi A & Harris KE 2002. Prevalence and onset of rhinitis and 
conjunctivitis in subjects with occupational asthma caused by trimellitic anhydride (TMA). 
Journal of Occupational and Environmental Medicine 44(12):1179–81.
Henneberger PK, Derk SJ, Davis L, Tumpowsky C, Reilly MJ, Rosenman KD et al. 2003. Work-
related reactive airways dysfunction syndrome cases from surveillance in selected US States. 
Journal of Occupational and Environmental Medicine 45(4):360–8.
Henneberger PK, Hoﬀman CD, Magid DJ & Lyons EE 2002. Work-related exacerbation of 
asthma. International Journal of Occupational and Environmental Health 8:291–6.
Hizawa N, Collins G, Rafnar T, Huang S-K, Duﬀy DL, Weber JL et al. 1998. Linkage analysis 
of Dermatophagoides pteronyssinus-speciﬁc IgE responsiveness with polymorphic markers on 
chromosome 6p21 (HLA-D region) in Caucasian families by the transmission/disequilibrium 
test. Collaborative Study on the Genetics of Asthma (CSGA). Journal of Allergy and Clinical 
Immunology 102:443–8.
Horne C, Quintana PJ, Keown PA, Dimich-Ward H & Chan-Yeung M 2000. Distribution of 
DRB1 and DQB1 HLA class II alleles in occupational asthma due to Western red cedar. 
European Respiratory Journal 15:911–4.
Host A & Halken S 2000. The role of allergy in childhood asthma. Allergy 55:600–8.
Huovinen E, Kaprio J, Laitinen LA & Koskenvuo M 1999. Incidence and prevalence of asthma 
among adult Finnish men and women of the Finnish Twin Cohort from 1975 to 1990, and 
their relation to hay fever and chronic bronchitis. Chest 115:928–36.
Illi S, von Mutius E, Lau S, Nickel R, Niggemann B, Sommerﬁeld C et al. 2001. The pattern 
of atopic sensitization is associated with the development of asthma in childhood. Journal of 
Allergy and Clinical Immunology 108:709–14.
Jaakkola MS, Ieromnimon A & Jaakkola JJK 2006. Are atopy and speciﬁc IgE to mites and moles 
important for adult asthma? Journal of Allergy and Clinical Immunology 117(3):642–8.
Johansson SGO, Hourihane J, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T et al. 
2001. A revised nomenclature for allergy: an EAACI position statement from the EAACI 
nomenclature task force. Allergy 56:813–24.
Johnson A, Dimich-Ward H, Manfreda J, Becklake MR, Ernst P, Sears MR et al. 2000. 
Occupational asthma in adults in six Canadian communities. American Journal of Respiratory 
and Critical Care Medicine 162:2058–62.
24
Occupational 
asthma in Aust
ralia
Johnson A, Hannaford-Turner K, Yates D, Sim M, Elder D & Abramson M 2006a. The 
surveillance of Australian workplace-based respiratory events (SABRE) scheme in Victoria, 
Tasmania and New South Wales. Respirology 11(S2):A64.
Johnson A, Toelle BG, Yates D, Belousova E, Ng K, Corbett S et al. 2006b. Occupational asthma 
in New South Wales (NSW): a population-based study. Occupational Medicine 56:258–62.
Karjalainen A, Kurppa K, Virtanen S, Keskinen H & Nordman H 2000. Incidence of 
occupational asthma by occupation and industry in Finland. American Journal of Industrial 
Medicine 37:451–8.
Karjalainen A, Martikainen R, Klaukka T, Saarinen K & Uitti J 2003. Risk of asthma among 
Finnish patients with occupational rhinitis. Chest 123:283–8.
Kim Y-K, Oh H-B, Oh S-Y, Cho S-H, Kim Y-Y & Min K-U 2001. HLA-DRB1*07 may have 
a susceptibility and DRB1*04 a protective eﬀect upon the development of a sensitization to 
house dust mite Dermatophagoides pteronyssinus. Clinical and Experimental Allergy 31:110–5.
Kogevinas M, Anto JM, Sunyer J, Tobias A, Kromhout H & Burney P 1999. Occupational 
asthma in Europe and other industrialised areas: a population-based study. The Lancet 
353:1750–4.
Kogevinas M, Zock J-P, JarvisD, Kromhout H, Lillienberg L, Plana E et al. 2007. Exposure to 
substances in the workplace and new-onset asthma: an international prospective population-
based study (ECRHS-II). The Lancet 370:336–41.
Larbanois A, Jamart J, Delwiche J-P & Vandenplas O 2002. Socioeconomic outcome of subjects 
experiencing asthma symptoms at work. European Respiratory Journal 19:1107–13.
Lombardo LJ & Balmes JR 2000. Occupational asthma: a review. Environmental Health 
Perspectives 108(S4):697–704. 
Malo J-L & Gautrin D 2007. From asthma in the workplace to occupational asthma. The Lancet 
370:295–7.
Malo J-L, Lemiere C, Desjardins A & Cartier A 1997. Prevalence and intensity of 
rhinoconjunctivitis in subjects with occupational asthma. European Respiratory Journal 
10:1513–5.
Malo J-L, Lemiere C, Gautrin D & Labrecque M 2004. Occupational asthma. Current Opinion 
in Pulmonary Medicine 10:57–61.
Mapp CE 2003. The role of genetic factors in occupational asthma. European Respiratory Journal 
22:173–8.
Mapp CE, Balboni A, Baricordi R & Fabbri LM 1997. Human leukocyte antigen associations in 
occupational asthma induced by isocyanates. American Journal of Respiratory and Critical 
Care Medicine 156:S139–43.
Mapp CE, Boschetto P, Maestrelli P & Fabbri LM 2005. Occupational asthma. American Journal 
of Respiratory and Critical Care Medicine 172(3):280–305.
McCunney RJ 2005. Asthma, genes, and air pollution. Journal of Occupational and 
Environmental Medicine 47(12):1285–91.
McDonald JC, Keynes HL & Meredith SK 2000. Reported incidence of occupational asthma in 
the United Kingdom, 1989–97. Occupational and Environmental Medicine 57:823–9.
Miraglia del Giudice M, Pedullà M, Piacentini GL, Capristo C, Brunese FP, Decimo F et al. 
2002. Atopy and house dust mite sensitization as risk factors for asthma in children. Allergy 
57:169–72.
Moscato G, Malo JL & Bernstein D 2003. Diagnosing occupational asthma: how, how much, how 
far? European Respiratory Journal 21:879–85.
National Asthma Education and Prevention Program 1997. Expert panel report 2: guidelines for 
the diagnosis and management of asthma. Clinical practice guidelines. NIH Publication No. 
97-4051. Bethesda, MD: National Heart, Lung, and Blood Institute.
bulletin 59 • april 2008
25
Newman Taylor A 2002. Asthma and work: the Colt Lecture, delivered at the Ninth 
International Symposium on Inhaled Particles, Cambridge, September 2001. Annals of 
Occupational Hygiene 46(7):563–74.
Newman Taylor AJ, Nicholson PJ, Cullinan P, Boyle C & Burge PS 2004. Guidelines for the 
prevention, identiﬁcation and management of occupational asthma: evidence review and 
recommendations. London: British Occupational Health Research Foundation.
Nicholson PJ, Cullinan P, Newman Taylor AJ, Burge PS & Boyle C 2005. Evidence based 
guidelines for the prevention, identiﬁcation, and management of occupational asthma. 
Occupational & Environmental Medicine 62:290–9.
Nieves A, Magnan A, Boniface S, Proudhon H, Lanteaume A, Romanet S et al. 2005. 
Phenotypes of asthma revisited upon the presence of atopy. Respiratory Medicine 99:347–54.
Novak N & Bieber T 2003. Allergic and nonallergic forms of atopic diseases. Journal of Allergy 
and Clinical Immunology 112:252–62.
O’Byrne PM & Inman MD 2003. Airway hyperresponsiveness. Chest 123:411–6.
Patino CM & Martinez FD 2001. Interactions between genes and environment in the 
development of asthma. Allergy 56:279–86.
Pearce N, Pekkanen J & Beasley R 1999. How much asthma is really attributable to atopy? 
Thorax 54:268–72.
Piirila P, Wikman H, Luukkonen R, Kaaria K, Rosenberg C, Nordman H et al. 2001. 
Glutathione S-transferase genotypes and allergic responses to diisocyanate exposure. 
Pharmacogenetics and genomics 11(5):437–45.
Plaschke P, Janson C, Norrman E, Björnsson E, Ellbjär S & Järvholm B 1999. Association 
between atopic sensitization and asthma and bronchial hyperresponsiveness in swedish 
adults: pets, and not mites, are the most important allergens. Journal of Allergy and Clinical 
Immunology 104:58–65.
Plaschke PP, Janson C, Norrman E, Björnsson E, Ellbjär S & Järvholm B 2000. Onset and 
remission of allergic rhinitis and asthma and the relationship with atopic sensitization and 
smoking. American Journal of Respiratory and Critical Care Medicine 162:920–4.
Porsbjerg C, von Linstow M-L, Ulrik CS, Nepper-Christensen S & Backer V 2006. Risk factors 
for onset of asthma: a 12-year prospective follow-up study. Chest 129(2):309–16.
Prescott SL & Tang M 2004. Position statement: allergy prevention in children. Australasian 
Society of Clinical Immunology and Allergy inc., Australia. Viewed 13 January 2006, email 
13 January 2006.
Reijula K, Haahtela T, Klaukka T & Rantanen J 1996. Incidence of occupational asthma and 
persistent asthma in young adults has increased in Finland. Chest 110:58–61.
Romero Jajosky RA, Harrison R, Reinisch F, Flattery J, Chan J, Tumpowsky C et al. 1999. 
Surveillance of work-related asthma in selected US states using surveillance guidelines for 
state health departments—California, Massachusetts, Michigan, and New Jersey, 1993–1995. 
Morbidity and Mortality Weekly Report 48:1–20.
Romieu I, Sienra-Monge JJ, Ramírez-Aguilar M, Moreno-Macías H, Reyes-Ruiz NI, 
Estela de Río-Navarro B et al. 2004. Genetic polymorphism of GSTM1 and antioxidant 
supplementation inﬂuence lung function in relation to ozone exposure in asthmatic children in 
Mexico City. Thorax 59:8–10.
Saarinen K, Karjalainen A, Martikainen R, Uitti J, Tammilehto L, Klaukka T et al. 2003. 
Prevalence of work-aggravated symptoms in clinically established asthma. European 
Respiratory Journal 22:305–9.
SABRE (Surveillance of Australian Workplace Based Respiratory Events) 2008. Results. Sydney: 
SABRE. Viewed 13 March 2008, <http://www.sabrensw.org/sabre_results.htm>.
26
Occupational 
asthma in Aust
ralia
Sastre J, Vandenplas O & Park H-S 2003. Pathogenesis of occupational asthma. European 
Respiratory Journal 22:364–73.
Senate Community Aﬀairs References Committee 2006. Workplace exposure to toxic dust. 
Canberra: The Senate.
Senechal H, Geny S, Desvaux FX, Busson M, Mayer C, Aron Y et al. 1999. Genetics and speciﬁc 
immune response in allergy to birch pollen and food: evidence of a strong, positive association 
between atopy and the HLA class II allele HLA-DR7. Journal of Allergy and Clinical 
Immunology 104:395–401.
Sim M, Abramson M, LaMontagne T, Aroni R, Elder D & Peeters A 2005. Occupational 
asthma—detection, surveillance and prevention of the disease burden. Final report. 
Melbourne: Monash University.
Soriano JB, Ercilla G, Sunyer J, Real FX, Lazaro C, Rodrigo MJ et al. 1997. HLA class II genes 
in soybean epidemic asthma patients. American Journal of Respiratory and Critical Care 
Medicine 156:1394–8.
Stephan V, Kuehr J, Seibt A, Saueressig H, Zingsem S, Dinh TD et al. 1999. Genetic linkage of 
HLA-class II locus to mite-speciﬁc IgE immune responsiveness. Clinical and Experimental 
Allergy 29:1049–54.
Tarlo SM, Banks DE, Liss G & Broder I 1997. Outcome determinants for isocyanate-induced 
occupational asthma among compensation claimants. Occupational and Environmental 
Medicine 11:220–34.
Tarlo SM & Liss GM 2003. Occupational asthma: an approach to diagnosis and management. 
Canadian Medical Association Journal 168(7):867–71.
van Woerden H 2004. Dust mites living in human lungs—the cause of asthma? Medical 
Hypotheses 63:193–7.
Vandenplas O & Malo JL 1997. Inhalation challenges with agents causing occupational asthma. 
European Respiratory Journal 10:2612–29.
Vandenplas O & Malo JL 2003. Deﬁnitions and types of work-related asthma: a nosological 
approach. European Respiratory Journal 21:706–12.
Vandenplas O, Toren K & Blanc PD 2003. Health and socioeconomic impact of work-related 
asthma. European Respiratory Journal 22:689–97.
Venables KM & Chan-Yeung M 1997. Occupational asthma. The Lancet 349:1465–9.
Wardlaw AJ, Silverman M, Siva R, Pavord ID & Green R 2005. Multi-dimensional phenotyping: 
towards a new taxonomy for airway disease. Clinical and Experimental Allergy 35:1254–62.
Wikman H, Piirila P, Rosenberg C, Luukkonen C, Kaaria R, Nordman K et al. 2002. N-
acetyltransferase genotypes as modiﬁers of diisocyanate exposure-associated asthma risk. 
Pharmacogenetics and genomics 12(3):227–33.
Wolfe R, Carlin JB, Oswald H, Olinsky A, Phelan PD & Robertson CF 2000. Association 
between allergy and asthma from childhood to middle adulthood in an Australian cohort 
study. American Journal of Critical Care Medicine 162:2177–81.
Xuan W, Marks GB, Toelle BG, Belousova E, Peat JK, Berry G et al. 2002. Risk factors for onset 
and remission of atopy, wheeze, and airway hyperresponsiveness. Thorax 57:104–9.
Yang IA, Savarimuthu S, Kim ST, Holloway JW, Bell SC & Fong KM 2007. Gene–
environmental interaction in asthma. Current Opinion in Allergy and Clinical Immunology 
7:75–82.
Youakim S 2001. Work-related asthma. American Family Physician 64(11):1839–48.
bulletin 59 • april 2008
27
Acknowledgments
The authors of this bulletin are Perri Timmins, Gabrielle Hodgson and Vanessa Prescott.
The authors acknowledge the input and helpful comments from Kuldeep Bhatia and 
Susan Killion from the Australian Institute of Health and Welfare, Guy Marks from the 
Australian Centre for Asthma Monitoring, and Anthony Hogan and Sophie Cartwright 
from the Oﬃce of the Australian Safety and Compensation Council.
Valuable guidance was received from the members of the Steering Committee of the 
Australian System for Monitoring Asthma during the drafting of this bulletin. Their 
input is greatly appreciated.
This publication was funded by the Australian Government through the Asthma 
Management Program 2005–09.
Abbreviations
HLA  human leucocyte antigen
HMW  high molecular weight
IgE  immunoglobulin E
LMW  low molecular weight
NDS  National Data Set for Compensation-based Statistics
RADS  reactive airways dysfunction syndrome
SABRE  Surveillance of Australian workplace Based Respiratory Events
© Australian Institute of Health and Welfare 2008
This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part 
may be reproduced without prior written permission from the Australian Institute of Health 
and Welfare. Requests and enquiries concerning reproduction and rights should be directed to 
the Head, Media and Communications, Australian Institute of Health and Welfare, GPO Box 570, 
Canberra ACT 2601.
This publication is part of the Australian Institute of Health and Welfare’s bulletin series. 
A complete list of the Institute’s publications is available on the Institute’s website 
<www.aihw.gov.au>.
ISSN 1446-9820 
ISBN 978 1 74024 773 3
Suggested citation
Australian Institute of Health and Welfare 2008. Occupational asthma in Australia.  
Bulletin no. 59. Cat no. AUS 101. Canberra: AIHW.
Australian Institute of Health and Welfare 
Board Chair  Director 
Hon. Peter Collins, AM, QC Penny Allbon
Any enquiries about or comments on this publication should be directed to:
Dr Kuldeep Bhatia 
Asthma, Arthritis and Environmental Health Unit 
Australian Institute of Health and Welfare 
GPO Box 570 
Canberra ACT 2601 
Phone 02 6244 1144 
Email: kuldeep.bhatia@aihw.gov.au
Published by the Australian Institute of Health and Welfare 
Printed by Elect Printing
